The Efficacy of Human Acellular Dermal Matrix in the Treatment of Anal Fistula
Launched by ZHEN JUN WANG · Jul 31, 2009
Trial Information
Current as of August 21, 2025
Unknown status
Keywords
ClinConnect Summary
Recently, the use of biomaterial for the treatment of anal fistula has drawn great interest. The advantages of this technique include simple and repeatable application, preservation of sphincter integrity, minimal patient discomfort, and the ability for subsequent surgical options if needed. Champagne et al reported using a biologic absorbable anal fistula plug which is made from lyophilized porcine small intestinal submucosa (Surgisis®). In their series of 46 patients treated with the anal fistula plug, a success rate of 83 percent was achieved at a median follow-up of 12 months. In additi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • complex anal fistula
- Exclusion Criteria:
- • pregnancy or lactation
- • with operation contraindication
- • allergic constitution to heterogeneous protein
- • complicated with tumor
- • complicated with acute infection
About Zhen Jun Wang
Zhen Jun Wang is a distinguished clinical trial sponsor dedicated to advancing medical research and innovation. With a focus on enhancing patient care, the organization specializes in designing and conducting clinical trials across various therapeutic areas. Zhen Jun Wang leverages a robust network of experienced professionals and cutting-edge methodologies to ensure rigorous study protocols and regulatory compliance. Committed to ethical practices and transparency, the sponsor aims to contribute valuable insights to the medical community, ultimately facilitating the development of effective treatments and improving health outcomes for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Beijing, Beijing, China
Beijing, Beijing, China
Beijing, Beijing, China
Beijing, Beijing, China
Beijing, Beijing, China
Shenzhen, Guangdong, China
Shijiazhuang, Hebei, China
Wuhan, Hubei, China
Shenyang, Liaoning, China
Jinan, Shandong, China
Jinan, Shandong, China
Shanghai, Shanghai, China
Patients applied
Trial Officials
Zhen Jun Wang, M.D.
Study Chair
Beijing Chao Yang Hospital
Ke Ding, M.D.
Principal Investigator
Second Affiliated Hospital of Medical College Shandong University
Chang Shun Wang, M.D.
Principal Investigator
Beijing Anorectal Hospital
Li Yong Wang, M.D.
Principal Investigator
The Central Hospital of China Aerospace Corporation
Li Ya Wang, M.D.
Principal Investigator
Children's Hospital of Hebei Province
Min Kong, M.D.
Principal Investigator
The 85th Hosptial of P.L.A
Xue Zhi Xin, M.D.
Principal Investigator
Shandong Provincial Hospital
Chao Wen Chen, M.D.
Principal Investigator
Peking University Third Hospital
Xiao Dong Yang, M.D.
Principal Investigator
Shenzhen People's Hospital
Ke Zhao, M.D.
Principal Investigator
The Second Artillery General Hospital
Bao Ming Zhao, M.D.
Principal Investigator
Dongzhimen Hospital, Beijing
Xian Dong Zeng, M.D.
Principal Investigator
Shenyang Anorectal Hospital
Si Tu Guang Wei, M.D.
Principal Investigator
Wuhan Iron and Steel Workers' Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials